The Middle East precision medicine market was estimated to be at $3,942.6 million in 2021, which is expected to grow with a CAGR of 7.37% and reach $8,620.0 million by 2032.

1. All rights reserved at BIS Research Inc. 1
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
Focus on Ecosystem, Technology,
Application, End User, and Country Data
Analysis and Forecast: 2022-2032
May 2022
Middle East
Precision
Medicine Market-
Country Analysis
Table of Content

2. All rights reserved at BIS Research Inc. 2
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3. All rights reserved at BIS Research Inc. 3
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
Table of Content
Executive Summary..........................................................................20
1 Middle East Precision Medicine Market ......................................22
1.1 Product Definition............................................................................................23
1.1.1 Inclusion and Exclusion .............................................................................23
1.1.2 Key Questions Answered in the Report ....................................................23
1.2 Research Methodology ...................................................................................24
1.2.1 Primary Data Sources .................................................................................24
1.2.2 Secondary Data Sources ............................................................................25
1.3 Market Estimation Model.................................................................................25
2 Market Overview........................................................................28
2.1 Market Definition..............................................................................................29
2.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric
Medicine ...........................................................................................................30
2.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to
Individually Tailored Therapy .........................................................................31
2.4 Precision Medicine: Enabling Technologies and Applications ...................31
2.4.1 Innovators....................................................................................................32
2.4.1.1 3D DNA Printing ................................................................................................ 32
2.4.1.1.1 Introduction .............................................................................................................. 32
2.4.1.1.2 Role of 3D DNA Printing .......................................................................................... 32
2.4.1.2 RNA-Seq............................................................................................................ 32
2.4.1.2.1 Introduction .............................................................................................................. 32
2.4.1.2.2 Role of RNA-Seq in Precision Medicine .................................................................. 32
2.4.1.2.3 Key Players.............................................................................................................. 33
2.4.1.3 4D Molecular Imaging........................................................................................ 33
2.4.1.3.1 Introduction .............................................................................................................. 33
2.4.1.3.2 Role of 4D Molecular Imaging in Precision Medicine .............................................. 33
2.4.1.3.3 Key Players.............................................................................................................. 33

4. All rights reserved at BIS Research Inc. 4
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
2.4.2 Early Adopters.............................................................................................33
2.4.2.1 Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)........... 33
2.4.2.1.1 Introduction .............................................................................................................. 33
2.4.2.1.2 Role of CRISPR in Precision Medicine.................................................................... 34
2.4.2.1.3 Key Players.............................................................................................................. 34
2.4.2.2 Blockchain ......................................................................................................... 35
2.4.2.2.1 Introduction .............................................................................................................. 35
2.4.2.2.2 Role of Blockchain in Precision Medicine ................................................................ 35
2.4.2.2.3 Key Players.............................................................................................................. 35
2.4.2.3 Imaging Informatics ........................................................................................... 36
2.4.2.3.1 Introduction .............................................................................................................. 36
2.4.2.3.2 Role of Imaging Informatics in Precision Medicine.................................................. 36
2.4.2.3.3 Key Players.............................................................................................................. 36
2.4.3 Early Majority...............................................................................................36
2.4.3.1 Artificial Intelligence (AI) .................................................................................... 36
2.4.3.1.1 Introduction .............................................................................................................. 36
2.4.3.1.2 Role of Artificial Intelligence in Precision Medicine.................................................. 37
2.4.3.1.3 Key Players.............................................................................................................. 37
2.4.3.2 Circulating Free DNA (cfDNA)........................................................................... 37
2.4.3.2.1 Introduction .............................................................................................................. 37
2.4.3.2.2 Role of cfDNA in Precision Medicine ....................................................................... 37
2.4.3.2.3 Key Players.............................................................................................................. 38
2.4.3.3 Big Data............................................................................................................. 38
2.4.3.3.1 Introduction .............................................................................................................. 38
2.4.3.3.2 Role of Big Data in Precision Medicine.................................................................... 38
2.4.3.3.3 Key Players.............................................................................................................. 39
2.4.3.4 Next-Generation Sequencing (NGS) ................................................................. 39
2.4.3.4.1 Introduction .............................................................................................................. 39
2.4.3.4.2 Role of NGS in Precision Medicine.......................................................................... 39
2.4.3.4.3 Key Players.............................................................................................................. 39

5. All rights reserved at BIS Research Inc. 5
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
2.4.3.5 Health Informatics.............................................................................................. 40
2.4.3.5.1 Introduction .............................................................................................................. 40
2.4.3.5.2 Role of Health Informatics in Precision Medicine .................................................... 40
2.4.3.5.3 Key players .............................................................................................................. 41
2.4.3.6 Bioinformatics .................................................................................................... 41
2.4.3.6.1 Introduction .............................................................................................................. 41
2.4.3.6.2 Role of Bioinformatics in Precision Medicine........................................................... 41
2.4.3.6.3 Key Players.............................................................................................................. 41
2.4.4 Late Majority ................................................................................................42
2.4.4.1 Polymerase Chain Reactions (PCR) ................................................................. 42
2.4.4.1.1 Introduction .............................................................................................................. 42
2.4.4.1.2 Role of PCR in Precision Medicine.......................................................................... 42
2.4.4.1.3 Key players .............................................................................................................. 42
2.4.4.2 Microarray.......................................................................................................... 42
2.4.4.2.1 Role of Microarray in Precision Medicine ................................................................ 43
2.4.4.2.2 Key Players.............................................................................................................. 43
2.5 COVID-19 Impact on the Middle East Precision Medicine Market ...............43
3 Industry Insights ........................................................................45
3.1 Patent Analysis................................................................................................46
3.2 Legal Requirements and Regulations............................................................46
4 Competitive Landscape .............................................................48
4.1 Synergistic Activities ......................................................................................49
4.2 Product Launches, Enhancements, and Upgradation..................................49
4.3 Mergers and Acquisitions...............................................................................50
4.4 Business Expansion........................................................................................51
5 Market Dynamics .......................................................................53
5.1 Market Drivers..................................................................................................54
5.1.1 Advancement of Sequencing Technologies .............................................54
5.1.2 Rising Prevalence of Chronic Diseases ....................................................54
5.1.3 Shifting the Significance in Medicine from Reaction to Prevention .......55

6. All rights reserved at BIS Research Inc. 6
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
5.1.4 Reducing Adverse Drug Reactions through Pharmacogenomics
Test...............................................................................................................55
5.1.5 Potential to Reduce the Overall Healthcare Cost Across the Globe.......56
5.2 Market Restraints.............................................................................................56
5.2.1 Unified Framework for Data Integration ....................................................56
5.2.2 Limited Knowledge about Molecular Mechanism/Interaction .................57
5.2.3 Lack of Robust Reimbursement Landscape.............................................58
5.3 Market Opportunities.......................................................................................58
5.3.1 Targeted Gene Therapy ..............................................................................58
5.3.2 Expansion into Emerging Markets.............................................................59
5.3.3 Collaborations and Partnerships across Value Chain to Accelerate
Market Entry.................................................................................................60
6 Middle East Precision Medicine Market, by Ecosystem,
$Million, 2021 - 2032 ..................................................................61
6.1 Overview...........................................................................................................62
6.2 Applied Sciences.............................................................................................63
6.3 Precision Therapeutics ...................................................................................65
6.4 Digital Health and Information Technology...................................................67
6.5 Precision Diagnostics .....................................................................................69
7 Middle East Precision Medicine Market, by Application,
$Million, 2021 - 2032 ..................................................................72
7.1 Overview...........................................................................................................73
7.2 Oncology ..........................................................................................................74
7.3 Infectious Diseases .........................................................................................76
7.4 Neurology.........................................................................................................77
7.5 Endocrinology..................................................................................................78
7.6 Cardiology........................................................................................................79
7.7 Gastroenterology.............................................................................................80
7.8 Other Applications...........................................................................................81
8 Middle East Precision Medicine Market, by End-User, $Million,
2021 - 2032................................................................................83

7. All rights reserved at BIS Research Inc. 7
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
8.1 Overview...........................................................................................................84
8.2 Biopharmaceutical Companies ......................................................................85
8.3 Diagnostic Companies ....................................................................................86
8.4 Other End Users ..............................................................................................87
9 Middle East Precision Medicine Market, by Country, $Million,
2021-2032..................................................................................88
9.1 Overview...........................................................................................................89
9.1.1 K.S.A.............................................................................................................90
9.1.2 Israel.............................................................................................................92
9.1.3 U.A.E.............................................................................................................93
9.1.4 Egypt ............................................................................................................94
9.1.5 Iran................................................................................................................95
9.1.6 Qatar.............................................................................................................95
9.1.7 Other Countries ...........................................................................................96
10 Market - Competitive Benchmarking & Company Profiles...........98
10.1 Overview...........................................................................................................99
10.2 Abbott. ............................................................................................................100
10.2.1 Company Overview ...................................................................................100
10.2.2 Role of Abbott. in the Middle East Precision Medicine Market..............100
10.2.3 Key Competitors of the Company............................................................100
10.2.4 Key Customers of the Company ..............................................................101
10.2.5 Financials...................................................................................................101
10.2.6 Key Insights about the Financial Health of the Company......................103
10.2.7 SWOT Analysis..........................................................................................104
10.3 Bio-Rad Laboratories, Inc. ............................................................................105
10.3.1 Company Overview ...................................................................................105
10.3.2 Role of Bio-Rad Laboratories, Inc. in the Middle East Precision
Medicine Market.........................................................................................105
10.3.3 Key Competitors of the Company............................................................105
10.3.4 Key Customers of the Company ..............................................................105

8. All rights reserved at BIS Research Inc. 8
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
10.3.5 Business Strategies ..................................................................................106
10.3.6 Financials...................................................................................................106
10.3.7 Key Insights about the Financial Health of the Company......................108
10.3.8 SWOT Analysis..........................................................................................109
10.4 ASURAGEN, INC............................................................................................110
10.4.1 Company Overview ...................................................................................110
10.4.2 Role of ASURAGEN, INC. in the Middle East Precision Medicine
Market.........................................................................................................110
10.4.3 Key Competitors of the Company............................................................110
10.4.4 Key Customers of the Company ..............................................................110
10.4.5 SWOT Analysis..........................................................................................111
10.5 bioMérieux SA................................................................................................112
10.5.1 Company Overview ...................................................................................112
10.5.2 Role of bioMérieux SA in the Middle East Precision Medicine Market
....................................................................................................................112
10.5.3 Key Competitors of the Company............................................................112
10.5.4 Key Customers of the Company ..............................................................112
10.5.5 Financials...................................................................................................113
10.5.6 Key Insights about the Financial Health of the Company......................115
10.5.7 SWOT Analysis..........................................................................................116
10.6 Diginova Health Solutions Ltd......................................................................117
10.6.1 Company Overview ...................................................................................117
10.6.2 Role of Diginova Health Solutions Ltd. in the Middle East Precision
Medicine Market.........................................................................................117
10.6.3 Key Competitors of the Company............................................................118
10.6.4 Key Customers of the Company ..............................................................118
10.6.5 Corporate Strategies.................................................................................118
10.6.5.1 Product Launches and Upgradation ................................................................ 118
10.6.6 SWOT Analysis..........................................................................................119
10.7 F. Hoffmann-La Roche Ltd............................................................................120
10.7.1 Company Overview ...................................................................................120

9. All rights reserved at BIS Research Inc. 9
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
10.7.2 Role of F. Hoffmann-La Roche Ltd in the Middle East Precision
Medicine Market.........................................................................................120
10.7.3 Key Competitors of the Company............................................................120
10.7.4 Key Customers of the Company ..............................................................120
10.7.5 Business Strategies ..................................................................................121
10.7.6 Corporate Strategies.................................................................................121
10.7.7 Key Insights about the Financial Health of the Company......................124
10.7.8 SWOT Analysis..........................................................................................125
10.8 GlaxoSmithKline plc......................................................................................126
10.8.1 Company Overview ...................................................................................126
10.8.2 Role of GlaxoSmithKline plc. in the Middle East Precision Medicine
Market.........................................................................................................126
10.8.3 Key Competitors of the Company............................................................126
10.8.4 Key Customers of the Company ..............................................................126
10.8.5 Financials...................................................................................................127
10.8.6 Key Insights about the Financial Health of the Company......................129
10.8.7 SWOT Analysis..........................................................................................130
10.9 Illumina, Inc....................................................................................................131
10.9.1 Company Overview ...................................................................................131
10.9.2 Role of Illumina, Inc. in the Middle East Precision Medicine Market ....131
10.9.3 Key Competitors of the Company............................................................131
10.9.4 Key Customers of the Company ..............................................................131
10.9.5 Financials...................................................................................................132
10.9.6 Key Insights about the Financial Health of the Company......................134
10.9.7 SWOT Analysis..........................................................................................135
10.10 Intomics..........................................................................................................136
10.10.1 Company Overview.............................................................................136
10.10.2 Role Intomics in the Middle East Precision Medicine Market .........136
10.10.3 Key Competitors of the Company .....................................................136
10.10.4 Key Customers of the Company........................................................136

10. All rights reserved at BIS Research Inc. 10
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
10.10.5 SWOT Analysis....................................................................................137
10.11 Merck KGaA ...................................................................................................138
10.11.1 Company Overview.............................................................................138
10.11.2 Role of Merck KGaA in the Middle East Precision Medicine
Market.........................................................................................................138
10.11.3 Key Competitors of the Company .....................................................139
10.11.4 Key Customers of the Company........................................................139
10.11.5 Financials ............................................................................................139
10.11.6 Key Insights about the Financial Health of the Company ...............141
10.11.7 SWOT Analysis....................................................................................142
10.12 Novartis AG....................................................................................................143
10.12.1 Company Overview.............................................................................143
10.12.2 Role of Novartis AG in the Middle East Precision Medicine
Market.........................................................................................................143
10.12.3 Key Competitors of the Company .....................................................143
10.12.4 Key Customers of the Company........................................................143
10.12.5 Financials ............................................................................................144
10.12.6 Key Insights about the Financial Health of the Company ...............146
10.12.7 SWOT Analysis....................................................................................147
10.13 Thermo Fisher Scientific Inc.........................................................................148
10.13.1 Company Overview.............................................................................148
10.13.2 Role of Thermo Fisher Scientific Inc. in the Middle East
Precision Medicine Market .......................................................................148
10.13.3 Key Competitors of the Company .....................................................149
10.13.4 Key Customers of the Company........................................................149
10.13.5 Financials ............................................................................................150
10.13.6 Key Insights about the Financial Health of the Company ...............152
10.13.7 SWOT Analysis....................................................................................153

11. All rights reserved at BIS Research Inc. 11
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
List of Figures
Figure 1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing, 2009-2025
Figure 2: Middle East Precision Medicine Market Segmentation
Figure 3: Primary Research Methodology
Figure 4: Bottom-Up Approach (Segment-Wise Analysis)
Figure 5: COVID-19 Impact on the Middle East Precision Medicine Market
Figure 6: Patent Analysis
Figure 7: Role of FDA in Advancing Precision Medicine
Figure 8: Synergistic Activities Share (by Company), January 2012-July 2020
Figure 9: Product Launches, Enhancements, and Upgradation Share (by Company), January 2012-July
2020
Figure 10: Mergers and Acquisitions Share (by Company), January 2012-July 2020
Figure 11: Business Expansion Share (by Company), January 2012-July 2020
Figure 12: Precision Medicine Ecosystem
Figure 13: Middle East Precision Medicine Market (Applied Sciences)
Figure 14: Middle East Precision Medicine Market (Applied Sciences), $Million, 2021-2032
Figure 15: Middle East Precision Medicine Market (by Applied Sciences), $Million, 2021-2032
Figure 16: Middle East Precision Medicine Market (Precision Therapeutics), $Million, 2021-2032
Figure 17: Middle East Precision Medicine Market (by Precision Therapeutics), $Million, 2021 and 2032
Figure 18: Middle East Precision Medicine Market (Digital Health and Information Technology), $Million,
2021-2032
Figure 19: Middle East Precision Medicine Market (by Digital Health and Information Technology),
$Million, 2021 and 2032
Figure 20: Middle East Precision Medicine Market (Precision Diagnostics)
Figure 21: Middle East Precision Medicine Market (Precision Diagnostics), $Million, 2021-2032
Figure 22: Middle East Precision Medicine Diagnostics Market (by Precision Diagnostics), $Million, 2021-
2032
Figure 23: Middle East Precision Medicine Market (by Application)
Figure 24: Middle East Precision Medicine Market (by Application), $Million, 2021 and 2032
Figure 25: Types of Cancer
Figure 26: Middle East Precision Medicine Market (Oncology), $Million, 2021-2032
Figure 27: Middle East Precision Medicine Market (Infectious Diseases), $Million, 2021-2032

12. All rights reserved at BIS Research Inc. 12
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
Figure 28: Clinical Trials Number in the Middle East, 2010 and 2020
Figure 29: Middle East Precision Medicine Market (Neurology), $Million, 2021-2032
Figure 30: Middle East Precision Medicine Market (Endocrinology), $Million, 2021-2032
Figure 31: Middle East Precision Medicine Market (Cardiology), $Million, 2021-2032
Figure 32: Middle East Precision Medicine Market (Gastroenterology), $Million, 2021-2032
Figure 33: Middle East Precision Medicine Market (Other Applications), $Million, 2021-2032
Figure 34: Middle East Precision Medicine Market (by End User)
Figure 35: Middle East Precision Medicine Market (by End User), $Million, 2021 and 2032
Figure 36: Middle East Precision Medicine Market, (Biopharmaceutical Companies), $Million, 2021-2032
Figure 37: Middle East Precision Medicine Market (Diagnostic Companies), $Million, 2021-2032
Figure 38: Middle East Precision Medicine Market (Other End Users), $Million, 2021-2032
Figure 39: Middle East Precision Medicine Market (by Country), $Million, 2021-2032
Figure 40: Middle East Precision Medicine Market (by Country), $Million, 2021 and 2032
Figure 41: Middle East Precision Medicine Market (K.S.A.), $Million, 2021-2032
Figure 42: Middle East Precision Medicine Market (Israel), $Million, 2021-2032
Figure 43: Middle East Precision Medicine Market (U.A.E.), $Million, 2021-2032
Figure 44: Middle East Precision Medicine Market (Egypt), $Million, 2021-2032
Figure 45: Middle East Precision Medicine Market (Iran), $Million, 2021-2032
Figure 46: Middle East Precision Medicine Market (Qatar), $Million, 2021-2032
Figure 47: Middle East Precision Medicine Market (Other Countries), $Million, 2021-2032
Figure 48: Total Number of Companies Profiled
Figure 49: Abbott.: Overall Product Portfolio
Figure 50: Abbott.: Overall Financials, $Million, 2019-2021
Figure 51: Abbott.: Revenue (by Segment), $Million, 2019-2021
Figure 52: Abbott.: Revenue (by Region), $Million, 2019-2021
Figure 53: Abbott.: R&D Expenditure, $Million, 2019-2021
Figure 54: Abbott.: SWOT Analysis
Figure 55: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
Figure 56: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 57: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 58: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 59: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 60: Bio-Rad Laboratories, Inc.: SWOT Analysis

13. All rights reserved at BIS Research Inc. 13
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
Figure 61: ASURAGEN, INC.: Overall Product Portfolio
Figure 62: ASURAGEN, INC.: SWOT Analysis
Figure 63: bioMérieux SA: Product Portfolio
Figure 64: bioMérieux SA: Overall Financials, $Million, 2019-2021
Figure 65: bioMérieux SA: Revenue (by Segment), $Million, 2019-2021
Figure 66: bioMérieux SA: Revenue (by Region), $Million, 2019-2021
Figure 67: bioMérieux SA: R&D Expenditure, $Million, 2019-2021
Figure 68: bioMérieux SA: SWOT Analysis
Figure 69: Diginova Health Solutions Ltd.: Product Portfolio
Figure 70: Diginova Health Solutions Ltd.: SWOT Analysis
Figure 71: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 72: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 73: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
Figure 74: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
Figure 75: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 76: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 77: GlaxoSmithKline plc.: Overall Product Portfolio
Figure 78: GlaxoSmithKline plc.: Overall Financials, $Million, 2019-2021
Figure 79: GlaxoSmithKline plc.: Revenue (by Segment), $Million, 2019-2021
Figure 80: GlaxoSmithKline plc.: Revenue (by Region), $Million, 2019-2021
Figure 81: GlaxoSmithKline plc.: R&D Expenditure, $Million, 2019-2021
Figure 82: GlaxoSmithKline plc.: SWOT Analysis
Figure 83: Illumina, Inc.: Product Portfolio
Figure 84: Illumina, Inc.: Overall Financials, $Million, 2019-2021
Figure 85: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 86: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 87: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 88: Illumina, Inc.: SWOT Analysis
Figure 89: Intomics: SWOT Analysis
Figure 90: Merck KGaA: Product Portfolio
Figure 91: Merck KGaA: Overall Financials, $Million, 2019-2021
Figure 92: Merck KGaA: Revenue (by Segment), $Million, 2019-2021
Figure 93: Merck KGaA: Revenue (by Region), $Million, 2019-2021

14. All rights reserved at BIS Research Inc. 14
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
Figure 94: Merck KGaA: R&D Expenditure, $Million, 2019-2021
Figure 95: Merck KGaA: SWOT Analysis
Figure 96: Novartis AG: Overall Product Portfolio
Figure 97: Novartis AG: Overall Financials, $Million, 2019-2021
Figure 98: Novartis AG: Revenue (by Segment), $Million, 2019-2021
Figure 99: Novartis AG: Revenue (by Region), $Million, 2019-2021
Figure 100: Novartis AG: R&D Expenditure, $Million, 2019-2021
Figure 101: Novartis AG: SWOT Analysis
Figure 102: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 103: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 104: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 105: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 106: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 107: Thermo Fisher Scientific Inc.: SWOT Analysis

15. All rights reserved at BIS Research Inc. 15
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
List of Tables
Table 1: Estimated Number of Cancer Incident Cases, 2018 and 2040

16. All rights reserved at BIS Research Inc. 16
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have the vision to be a leading and preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

17. All rights reserved at BIS Research Inc. 17
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies.
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

18. All rights reserved at BIS Research Inc. 18
M
I
D
D
L
E
E
A
S
T
P
R
E
C
I
S
I
O
N
M
E
D
I
C
I
N
E
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com